TITLE
Recommendation to authorize City Manager, or designee, to execute a Master Agreement between the City of Long Beach and the County of Los Angeles Department of Public Health (LADPH), and any subsequent amendments, to provide Biomedical Human Immunodeficiency Virus Prevention Services for a term effective upon the date of execution and continuing through December 31, 2023, with an option to extend the agreement for two additional one-year terms at the discretion of the LADPH through December 31, 2025. (Citywide)
DISCUSSION
In 2012, the first biomedical HIV prevention intervention for HIV negative individuals was implemented with the approval of the Food and Drug Administration (FDA) of the drug Truvada for use as a Pre-exposure prophylaxis, also known as PrEP. PrEP, is a HIV prevention prescription medication (Truvada) for people who do not have HIV, but who are at substantial risk of contracting HIV. PrEP, as a biomedical prevention intervention, has been proven safe and effective in reducing the risk of HIV infection in people who are at high risk by up to 92 percent when taken consistently.
The Department of Health & Human Services (Health Department) HIV Care Clinic’s medical providers have nearly three years of experience in providing biomedical HIV prevention services as co-investigators of a multi-year study led by the California Collaborative Treatment Group (CCTG), sponsored by the California Research Program (CHRP) and the Centers for Disease Control (CDC).
In October 2015, the Health Department began expanding its PrEP services to include those outside of the current study as a billable service under Medi-Cal, Medicare and other third party payers. This agreement will enable the Health Department to be eligible to contract with the LADPH to provide biomedical HIV prevention services in the community targeting individuals who are uninsured/underinsured and at substantial risk for contracting HIV.
This matter was reviewed by Deputy City Att...
Click here for full text